It is a key task for cancer research to search novel prognostic marker, improve early diagnostic rate, and new target of molecular targeted therapy of gastric cancer.
因此提高胃癌的早期诊断率、寻找新的治疗靶点及预后指标，是当前肿瘤研究的重要课题。
Molecular targeted therapy has limited or nonexistent side effects on normal cells of the body, unlike traditional chemotherapy.
分子靶向治疗比传统的化疗特异性强、毒副反应小，将成为今后肿瘤治疗的新趋势。
Objective to get an insight into the molecular mechanisms of diseases development and targeted therapy at the transcriptome level and search for potential therapeutic targets.
目的在转录组水平全面迅速地了解疾病发生和药物作用的分子机理，以及寻找潜在的治疗靶标。
The molecular targeted therapy for esophageal cancer, still in its infancy, is also an important area of the study in future esophageal cancer treatment.
而对于食管癌的分子靶向治疗，目前尚处于萌芽阶段，也是食管癌治疗研究的重点，并具有广阔的前景。
In recent years, molecular targeted therapy has become a hot spot.
近年来分子靶向治疗逐渐成为研究热点。
For patients who are inoperable and in the advanced stage, chemotherapy combined with molecular targeted therapy can have better therapeutic effect.
对晚期不能手术的患者采用先化疗后分子靶向治疗的续贯疗法可取得较好的疗效。
Even someone posed that OPN can be regarded as a target for molecular targeted therapy of many kinds of tumors.
甚至有人提出OPN可以作为肿瘤分子靶向治疗的一个靶点。
KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.
KRAS基因突变在恶性肿瘤组织中频发，可预测非小细胞肺癌分子靶向治疗的疗效和预后，针对RAS基因的分子抑制剂研究仍处于初级阶段。
Molecular targeted therapy has a advance development, the molecular targeted therapies drug for epidermal growth factor receptor (EGFR) present definite clinic effect.
肺癌分子靶向治疗近年来取得较大进展，特别是针对表皮生长因子受体(EGFR)分子靶向药物表现出确定的临床效果。
The immunotherapy and chemotherapeutics confirmed existence certain curative effect, Molecular staging and targeted therapy may will be the new tendency in future.
免疫治疗、化疗被证实存在一定疗效。分子靶向研究是恶性黑色素瘤治疗的新趋势。
The systemic therapy of non-small cell lung cancer (NSCLC) is moving away from the "one-size fits all" empiric chemotherapy to targeted therapy of specific molecular alternations.
非小细胞肺癌的系统治疗已经由“一刀切”的经典化疗转变为针对特异分子改变的靶向治疗。
The systemic therapy of non-small cell lung cancer (NSCLC) is moving away from the "one-size fits all" empiric chemotherapy to targeted therapy of specific molecular alternations.
非小细胞肺癌的系统治疗已经由“一刀切”的经典化疗转变为针对特异分子改变的靶向治疗。
应用推荐